Therapeutic management of post-kidney transplant hyperparathyroidism

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 24-39

  Copley, John B ^a   Wüthrich, Rudolf P ^b  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Bone disease; Calcimimetics; Hypercalcemia; Kidney transplantation; Persistent hyperparathyroidism

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; DIHYDROTACHYSTEROL; DOXERCALCIFEROL; ETIDRONIC ACID; FIBROBLAST GROWTH FACTOR 23; IBANDRONIC ACID; PAMIDRONIC ACID; PARICALCITOL; PHOSPHORUS; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; CALCIFICATION; CALCIUM BLOOD LEVEL; GRAFT SURVIVAL; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION;

CALCIUM; HUMANS; HYPERPARATHYROIDISM; KIDNEY TRANSPLANTATION; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROIDECTOMY; TREATMENT OUTCOME;

EID: 79551693376     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01287.x     Document Type: Review

References (141)

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999: 341: 1725.
2. Raine AE, Margreiter R, Brunner FP et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992: 7(Suppl 2): 7.
3. Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc 2007: 39: 3153.
4. Rojas E, Carlini RG, Clesca P et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003: 63: 1915.
5. Bonomini V, Feletti C, Di Felice A, Buscaroli A. Bone remodelling after renal transplantation (RT). Adv Exp Med Biol 1984: 178: 207.
6. Nielsen HE, Melsen F, Christensen MS. Aseptic necrosis of bone following renal transplantation. Clinical and biochemical aspects and bone morphometry. Acta Med Scand 1977: 202: 27.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003: 42(4 Suppl 3): S1.
8. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000: 14: 342.
9. Lobo PI, Cortez MS, Stevenson W, Pruett TL. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995: 9: 277.
10. Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998: 13(Suppl 3): 94.
11. Rangbar-Omrani G, Dabbaghmanesh M-H, Soleimani M, Roozbeh J, Raiss-Jalali G-A, Behzadi S. Predictive factors for persistent hyperparathyroidism after kidney transplantation. Arch Iran Med 2005: 8: 295.
12. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002: 13: 551.
13. Boom H, Mallat MJ, De Fijter JW, Paul LC, Bruijn JA, Van Es LA. Calcium levels as a risk factor for delayed graft function. Transplantation 2004: 77: 868.
14. Ozdemir FN, Afsar B, Akgul A, Usluogullari C, Akcay A, Haberal M. Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 2006: 38: 480.
15. Egbuna OI, Zand MS, Taylor JG, Bushinsky DA. Abnormal mineral metabolism and outcomes after renal transplantation [abstract # F-FC028]. J Am Soc Nephrol 2005: 16: 88A.
16. Pande S, Ritter CS, Rothstein M et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006: 104: 23.
17. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003: 64: 2272.
18. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004: 19: 429.
19. Razzaque MS, St-Arnaud R, Taguchi T, Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 2005: 20: 2032.
20. Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998: 54: 1704.
21. Bertoni E, Rosati A, Larti A et al. Chronic kidney disease is still present after renal transplantation with excellent function. Transplant Proc 2006: 38: 1024.
22. Gourishankar S, Hunsicker LG, Jhangri GS, Cockfield SM, Halloran PF. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003: 14: 2387.
23. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993: 92: 1436.
24. Lewin E. Involution of the parathyroid glands after renal transplantation. Curr Opin Nephrol Hypertens 2003: 12: 363.
25. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000: 14: 457.
26. Harach HR, Jasani B. Parathyroid hyperplasia in tertiary hyperparathyroidism: a pathological and immunohistochemical reappraisal. Histopathology 1992: 21: 513.
27. Taniguchi M, Tokumoto M, Matsuo D et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int 2006: 70: 363.
28. Houssaini T, Arrayhani M, Rhou H et al. Predictors of hyperparathyroidism in renal transplant recipients. Saudi J Kidney Dis Transpl 2008: 19: 401.
29. Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999: 34: 87583.
30. Levi M. Post-transplant hypophosphatemia. Kidney Int 2001: 59: 2377.
31. Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006: 2: 136.
32. Madsen S, Olgaard K, Lund B, Lund B, Sorensen OH. Pathogenesis of hypophosphataemia in kidney necrograft recipients: a controlled trial. Proc Eur Dial Transplant Assoc 1979: 16: 618.
33. Felsenfeld AJ, Gutman RA, Drezner M, Llach F. Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1, 25-dihydroxycholecalciferol. Miner Electrolyte Metab 1986: 12: 333.
34. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int 2006: 70: 1486.
35. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000: 26: 345.
36. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004: 23: 421.
37. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007: 293: F1577.
38. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007: 27: 3417.
39. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of Fibroblast Growth Factor-23 Signaling by Klotho. J Biol Chem 2006: 281: 6120.
40. Schankel K, Robinson J, Bloom RD et al. Determinants of Coronary Artery Calcification Progression in Renal Transplant Recipients. Am J Transplant 2007: 7: 2158.
41. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007: 194: 1.
42. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003: 285: E1.
43. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphateia. N Engl J Med 2003: 348: 1656.
44. Jacob HS, Amsden T. Acute hemolytic anemia with rigid red cells in hypophosphatemia. N Engl J Med 1971: 285: 1446.
45. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007: 7: 1193.
46. Evenepoel P, Van Den Bergh B, Naesens M et al. Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol 2009: 4: 665.
47. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004: 19: 1281.
48. Cundy T, Kanis JA, Heynen G, Morris PJ, Oliver DO. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983: 52: 67.
49. Ramezani M, Einollahi B, Asl MA et al. Calcium and phosphorus metabolism disturbances after renal transplantation. Transplant Proc 2007: 39: 1033.
50. Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant 2007: 7: 2546.
51. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998: 13: 436.
52. Schwartz GH, David DS, Riggio RR et al. Hypercalcemia after renal transplantation. Am J Med 1970: 49: 42.
53. Straffen AM, Carmichael DJ, Fairney A, Hulme B, Snell M. Calcium metabolism following renal transplantation. Ann Clin Biochem 1994: 31(Pt 2): 125.
54. Babarykin D, Adamsone I, Amerika D, Folkmane I, Rozental R. Disorders of calcium metabolism at various times after renal transplantation. Ann Transplant 1999: 4: 46.
55. Fassi J, Rosa Diez G, Imperiali N, Groppa R, Giordani MC, Plantalech L. Prevalence of hypercalcemia following kidney transplantation. Bone 2007: 41: S11.
56. Roe SD, Porter CJ, Godber IM, Hosking DJ, Cassidy MJ. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos Int 2005: 16: 142.
57. Iwasaki Y, Yamato H, Nii-Kono T et al. Insufficiency of PTH action on bone in uremia. Kidney Int 2006: 70: S34.
58. David DS, Sakai S, Brennan BL et al. Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973: 289: 398.
59. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005: 5: 1934.
60. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004: 15: 2857.
61. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005: 289: F8.
62. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005: 79: 108.
63. Steiner RW, Ziegler M, Halasz NA, Catherwood BD, Manolagas S, Deftos LJ. Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 1993: 56: 843.
64. Ewers B, Gasbjerg A, Moelgaard C, Frederiksen AM, Marckmann P. Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr 2008: 87: 431.
65. Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant 2006: 21: 2621.
66. Lomonte C, Antonelli M, Vernaglione L et al. Are low plasma levels of 25-(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients? J Nephrol 2005: 18: 96.
67. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006: 17: 1305.
68. Carlini RG, Rojas E, Weisinger JR et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000: 36: 160.
69. Schwarz A, Mengel M, Gwinner W et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005: 67: 341.
70. Mazzaferro S, Pasquali M, Taggi F et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009: 4: 685.
71. Oschatz E, Benesch T, Kodras K, Hoffmann U, Haas M. Changes of coronary calcification after kidney transplantation. Am J Kidney Dis 2006: 48: 307.
72. Rosas SE, Mensah K, Weinstein RB, Bellamy SL, Rader DJ. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005: 5: 1942.
73. Moe SM, O'Neill KD, Resterova M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004: 19: 2387.
74. Djamali A, Samaniego M, Muth B et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 2006: 1: 623.
75. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002: 346: 580.
76. Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Horl WH, Oberbauer R. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol 2008: 19: 2211.
77. Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005: 20: 1714.
78. Rostaing L, Moreau-Gaudry X, Baron E, Cisterne JM, Monrozies-Bernadet P, Durand D. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997: 47: 248.
79. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996: 97: 2167.
80. Lee PP, Schiffmann L, Offermann G, Beige J. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res 2004: 27: 191.
81. Kerby JD, Rue LW, Blair H, Hudson S, Sellers MT, Diethelm AG. Operative treatment of tertiary hyperparathyroidism: a single-center experience. Ann Surg 1998: 227: 878.
82. Triponez F, Kebebew E, Dosseh D et al. Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. Surgery 2006: 140: 990; discussion 997-9.
83. Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007: 7: 2515.
84. Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001: 38(Pt 6): 608.
85. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003: 14: 2669.
86. El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005: 67: 2039.
87. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int 2000: 57: 684.
88. Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 2003: 63: 2275.
89. Grotz W, Nagel C, Poeschel D et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001: 12: 1530.
90. Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003: 63: 1130.
91. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003: 76: 1498.
92. Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 2002: 34: 2111.
93. Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006: 21: 2275.
94. Nowacka-Cieciura E, Cieciura T, Baczkowska T et al. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 2006: 38: 165.
95. Arlen DJ, Lambert K, Ioannidis G, Adachi JD. Treatment of established bone loss after renal transplantation with etidronate. Transplantation 2001: 71: 669.
96. Torregrosa JV, Moreno A, Gutierrez A, Vidal S, Oppenheimer F. Alendronate for treatment of renal transplant patients with osteoporosis. Transplant Proc 2003: 35: 1393.
97. Giannini S, D'Angelo A, Carraro G et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001: 16: 2111.
98. Rodd C. Bisphosphonates in dialysis and transplantation patients: efficacy and safety issues. Perit Dial Int 2001: 21(Suppl 3): S256.
99. Jansson S, Morgan E. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism. World J Surg 2004: 28: 1293.
100. Miacalcin PI. Miacalcin® (Calcitonin-Salmosn) Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corp., 2006.
101. Grotz WH, Rump LC, Niessen A et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998: 66: 10048.
102. Caravaca F, Fernandez MA, Ruiz-Calero R et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998: 13: 2605.
103. Portale AA, Halloran BP, Murphy MM, Morris RC Jr. Oral intake of phosphorus can determine the serum concentration of 1, 25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986: 77: 7.
104. De Sevaux RG, Hoitsma AJ, Van Hoof HJ, Corstens FJ, Wetzels JF. Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract 2003: 93: C21.
105. Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 2006: 91: 526.
106. Cueto-Manzano AM, Konel S, Freemont AJ et al. Effect of 1, 25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000: 35: 227.
107. El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant 2004: 4: 2052.
108. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 2004: 78: 1233.
109. Torres A, Garcia S, Gomez A et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004: 65: 705.
110. Berczi C, Asztalos L, Kincses Z et al. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation. Osteoporos Int 2003: 14: 412.
111. O'Herrin JK, Hullett DA, Heisey DM, Sollinger HW, Becker BN. A retrospective evaluation of 1, 25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002: 22: 515.
112. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006: 69: 33.
113. Courbebaisse M, Thervet E, Souberbielle JC et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009: 75: 646.
114. Brown AJ, Coyne DW. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol 2002: 1: 313.
115. Copley J, Germain M, Stern L et al. Evaluation of cinacalcet HCl treatment following renal transplantation. Transplant Proc 2010: in press.
116. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005: 20: 1311.
117. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006: 6: 2391.
118. Leonard N, Brown JH. Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet. Nephrol Dial Transplant 2006: 21: 1736.
119. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007: 22: 577.
120. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005: 20: 1315.
121. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006: 1: 323326.
122. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006: 82: 675.
123. El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007: 83: 546.
124. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 1999: 10: 66.
125. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004: 308: 627.
126. Block GA, Martin KJ, De Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004: 350: 1516.
127. Chertow GM, Blumenthal S, Turner S et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006: 1: 305.
128. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005: 16: 800.
129. Sterrett JR, Strom J, Stummvoll HK et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007: 68: 10.
130. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007: 22: 2362.
131. Serra AL, Wuhrmann C, Wuthrich RP. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 2008: 52: 1151.
132. Kamar N, Gennero I, Spataru L et al. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrol Dial Transplant 2008: 23: 3720.
133. Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008: 86: 413.
134. Chattopadhyay N, Cheng I, Rogers K et al. Identification and localization of extracellular Ca(2+)-sensing receptor in rat intestine. Am J Physiol 1998: 274(1 Pt 1): G122.
135. Serra AL, Braun SC, Starke A et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008: 8: 803.
136. Boulanger H, Haymann JP, Fouqueray B et al. Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. Nephrol Dial Transplant 2005: 20: 2865.
137. Esposito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N. Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. Clin Nephrol 2007: 68: 245.
138. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl 2006: 70(Suppl 102): S3.
139. Drueke TB. Therapeutic failure of cinacalcet in a renal transplant patient. Nephrol Dial Transplant 2006: 21: 824; author reply 824-5.
140. Peng LW, Logan JL, James SH, Scott KM, Lien YH. Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient. Am J Med 2007: 120: e7.
141. Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics 2005: 15: 29.